Attovia Therapeutics Stock Surges 24% in Nasdaq Debut After $289 Million IPO

Attovia Therapeutics (NASDAQ:ATTO) made a strong public market debut on Monday, with its shares surging 24% after the company raised $289 million in its initial public offering, signaling robust investor appetite for new biotech listings.

The stock opened for trading in New York at $21 per share, significantly above its IPO price of $17. The performance gives the company a market capitalization of nearly $904 million, based on the outstanding shares detailed in its public filings.

IPO Details

Attovia priced 17 million shares at $17 apiece to raise the $289 million in gross proceeds. The offering also grants underwriters a 30-day option to purchase up to an additional 2.55 million shares at the IPO price, less commissions.

The offering is expected to formally close on August 6, 2026, subject to the satisfaction of customary closing conditions. A syndicate of investment banks, including Morgan Stanley, Leerink Partners, Citigroup, and RBC Capital Markets, acted as joint book-running managers for the deal.

Ad

Corporate Background

Attovia is a clinical-stage biopharmaceutical company that was established in 2023 by Alamar Biosciences Inc. The company is developing drugs using a technology platform and patents licensed from Alamar, which focuses on medical devices for protein analysis and disease detection.

Alamar, which remains an investor in Attovia, also had a successful market entry. The device maker raised $219.9 million in its own IPO in April, and its shares have climbed nearly 70% since their debut. This prior success may have contributed to positive sentiment surrounding Attovia's offering.